drugset / Trial / NCT04510090
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
Phase 1
Completed
89 enrolled
Escient Pharmaceuticals, Inc
Novotech (Australia) Pty Limited · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This first in human, Phase 1/1b trial will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of EP547 in healthy subjects and subjects with cholestatic or uremic pruritus.
Timeline
- Start
- 2020-09-07
- Primary completion
- 2021-07-08
- Completion
- 2021-07-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EP547 | Unknown | — | — |